External quality assessment (EQA) for CoaguChek monitors

Joergen Jespersen; Leon Poller; A. M. H. P. van den Besselaar; Felix J. M. van der Meer; Gualtiero Palareti; Armando Tripodi; Caroline Shiach; Michelle Keown; Saied Ibrahim

doi:10.1160/TH09-10-0683

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2010; 103(05): 936-941
DOI: 10.1160/TH09-10-0683

Theme Issue Article

Schattauer GmbH

External quality assessment (EQA) for CoaguChek monitors

Joergen Jespersen

¹Department of Clinical Biochemistry, Hospital of South West Denmark, Esbjerg and Department for Thrombosis Research, Institute of Public Health, University of Southern Denmark, Esbjerg, Denmark

,

Leon Poller

²EAA Central Facility, Faculty of Life Sciences, University of Manchester, Manchester, UK

,

A. M. H. P. van den Besselaar

³Department of Thrombosis and Haemostasis, Leiden University Medical Center, Leiden, The Netherlands

,

Felix J. M. van der Meer

⁴Department of Thrombosis and Haemostasis, Leiden University Medical Center, Thrombosis Service Leiden, Leiden, The Netherlands

,

Gualtiero Palareti

⁵Department of Angiology and Blood Coagulation, University Hospital Sant’Orsola-Malpighi, Bologna, Italy

,

Armando Tripodi

⁶University and IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy

,

Caroline Shiach

⁷Department of Haematology, Manchester Royal Infirmary, Oxford Road, Manchester, UK

,

Michelle Keown

²EAA Central Facility, Faculty of Life Sciences, University of Manchester, Manchester, UK

,

Saied Ibrahim

²EAA Central Facility, Faculty of Life Sciences, University of Manchester, Manchester, UK

› Author Affiliations

Abstract

Summary

Anticoagulant control facilities are being overwhelmed by requests for monitoring and large numbers of patients are not therefore receiving treatment. Procedures designed for point-of-care testing have therefore been developed, the most popular being the CoaguChek. The need for external quality assessment (EQA) of monitors used by patients in self-management has been stressed in a European Commission (EC) Directive. It would not however be feasible for all CoaguChek monitors to be enrolled in national or regional EQA schemes which take time to organise and analyse. The European Concerted Action on Anticoagulation (ECAA) has therefore evolved a simpler system. Its value has been assessed in collaboration with the European Concerted Action on Thrombosis (ECAT). 523 monitors were tested at nine clinics which asked patients to bring their CoaguChek instruments to be assessed with the ECAA/ECAT procedure based on a set of 5 plasma samples with certified international normalised ratios (INR). 15% or more deviation from the certified INR on a single certified plasma sample from the set was defined by the ECAA as the limit of acceptable performance. One hundred and six (20.3%) of the monitors tested showed significant deviation and higher than average incidence of significant INR deviations reported with one specific numbered lot of test strips. Recent ECAA/ECAT, Danish and Italian studies report regular EQA of CoaguChek monitors is essential. There is general agreement that this should be performed at reasonably frequent intervals, at six months or whenever there is a change of the manufacturer’s test strips.

Keywords

Oral anticoagultaion - external quality assessment - point-of-care monitors - INR deviation - accuracy, precision

Full Text

References

References
1 Cannegieter SC, Rosendaal FR, Wintzen AR. et al. Optimal oral anticoagulant therapy in patients with mechanical heart valves. New Engl J Med 1995; 333: 11-17.
2 Poller L. Precision and accuracy of CoaguChek S and XS monitors: the need for external quality assessment. Thromb Haemost 2009; 101: 419-421.
3 Tripodi A, Arbini AA, Chantarangkul V. et al. Are capillary whole blood coagulation monitors suitable for the control of oral anticoagulant treatment by the International Normalized Ratio?. Thromb Haemost 1993; 70: 921-924.
4 WHO Guidelines for thromboplastins and plasma used to control oral anticoagulation therapy.. Annex 3. WHO Technical Report Series 1999; 889: 64-93.
5 ISO/IEC. Guide 43–1, Proficiency testing by interlaboratory comparisons – Part 1: Development and operation of proficiency testing schemes.
6 European Commission Directive. 1998 (98/79/EC). In vitro diagnostic medical devices.
7 Poller L, Keown M, Chauhan N. et al. Normalisation and Standardisation of Home PT Monitors (SMT4-CT98–2269). European Concerted Action on Anticoagulation Technology Implementation Plan 2002 EC Brussels.
8 Poller L, Keown M, Ibrahim SA. et al. Quality Assessment of CoaguChek Point-of-Care Prothrombin Time Monitors: Comparison of the European Community-Approved Procedure and Conventional External Quality Assessment. Clin Chem 2006; 52: 1843-1847.
9 Meijer P, Kluft C, Poller L. et al. A National Field Study of Quality Assessment of CoaguChek Point-of-Care Testing Prothrombin Time Monitors. Am J Clin Pathol 2006; 126: 756-761.
10 Poller L, Keown M, Chauhan N. et al. An assessment of lyophilised plasmas for ISI calibration of CoaguChek and TAS whole blood prothrombin time monitors. J Clin Pathol 2003; 56: 114-119.
11 Poller L, Keown M, van den Besselaar AMHP. et al. The Use of ECAA Calibrant Plasmas for Quality Control of Home PT Monitors-Inter Lot Variability of Test Strips/Cartridges. Thromb Haemost 2001; Suppl: 1418.
12 Poller L, Keown M, Chauhan N. et al. Reliability of International Normalised Ratios (INR) from CoaguChek Mini and TAS PT-NC whole blood point-of-care test monitor systems. BMJ 2003; 327: 30-34.
13 Meijer P. Results of a pilot study on external quality control for the CoaguChek S and XS INR measurement and proposals for an external quality control programme for the CoaguChek S and XS. Danish Society of Thrombosis and Haemostasis Forum. Abstract 2009; 02: P9-14.
14 Plesch W, Wolf T, Breitenbeck N. et al. Results of the performance verification of the CoaguChek XS system. Thromb Res 2008; 123: 381-389.
15 Christensen TD, Larsen TB, Jensen C. et al. International Normalized Ratio (INR) measured on the CoaguChek S and XS compared with the laboratory using repeated measurements for determination of precision and accuracy. Thromb Haemost 2009; 101: 563-569.
16 Barcellona D, Fenu L, Cornacchini S. et al. Point-of-care (POCT) prothrombin time monitors: is a periodical control of their performance useful?. Thromb Res 2009; 123: 775-779.
17 Connock M, Stevens C, Fry-Smith A. et al. Clinical effectiveness and cost-effectiveness of different models of managing long-term oral anticoagulation therapy: a systematic review and economic modelling. Health Technol Assess 2007; 11: 1-86.
18 Ansell J, Hirsh J, Poller L. et al. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126: 212S.
19 Kitchen S, Kitchen DP, Jennings I. et al. Point-of-care International Normalised Ratios: UK NEQAS experience demonstrates necessity for proficiency testing of three different monitors. Thromb Haemost 2006; 96: 590-596.
20 Poller L, Keown M, Chauhan N. et al. Comparison of fresh plasma and whole blood multicentre ISI calibrations of CoaguChek Mini and TAS PT-NC whole blood prothrombin time point-of-care monitors. Thromb Haemost 2002; 87: 859-866.
21 Poller L, Keown M, Chauhan N. et al. Quality assessment of two point-of-care whole blood prothrombin time monitor systems (CoaguChek Mini and TAS PTNC). Clin Chem 2004; 50: 537-544.
22 Braun S, Watzke H, Hasenkam JM. et al. Performance evaluation of the new CoaguChek XS system compared with the established CoaguChek system by patients experienced in INR-self management. Thromb Haemost 2007; 97: 310-314.
23 Leichsenring I, Plesch W, Unkrig V. et al. Multicentre ISI assignment and calibration of the INR measuring range of a new point-of-care system designed for home monitoring of oral anticoagulant therapy. Thromb Haemost 2007; 97: 856-861.